Date: 2017-11-20
Type of
information: Publication of results in a medical journal
phase:
Announcement: publication of results in Molecular Therapy — Nucleic Acids
Company: Cellectis (France)
Product: TAL nucleases (TALEN®) targeting PD1
Action
mechanism: gene editing technology
Disease:
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On November 20, 2017, Cellectis announced the
publication of a study in Molecular Therapy — Nucleic Acids describing the educated engineering of highly specific and efficient TAL nucleases (TALEN®) targeting PD1, a key T-cell immune checkpoint. In this report, Anne-Sophie Gautron, Ph.D., Alexandre Juillerat, Ph.D., and their collaborators used a strategy developed by Cellectis to control TALEN® targeting based on a proprietary technology leveraging the exclusion capacities of non-conventional
RVDs. This approach allows combined disruptions of the desired TRAC and PDCD1 loci by TALEN® while eliminating low frequency off-site processing. By adjusting a few RVDs, they provided a rapid and straightforward redesign of optimal TALEN® combinations for multiplex gene editing. This approach can greatly benefit gene editing for therapeutic applications where high editing efficiencies need to be associated with maximal specificity and safety.
- (Fine and predictable tuning of TALEN gene editing targeting for improved T-cell adoptive immunotherapy. Anne-Sophie Gautron1,3, Alexandre Juillerat2,3, Valérie Guyot1, Jean-Marie Filhol1, Emilie Dessez1, Aymeric Duclert1, Philippe Duchateau1 and Laurent Poirot. Molecular Therapy - Nucleic Acids - Volume 9, 15 December 2017, Pages 312-321)
Is
general: Yes
